Systemic Therapy

Systemic therapy refers to any cancer treatment that travels through the bloodstream to reach cells throughout the body, rather than targeting a single area. In mesothelioma and other asbestos-related cancers, this category includes chemotherapy, immunotherapy, targeted therapy, and certain hormone or biologic agents. It is contrasted with local treatments like surgery and radiation, which act only on a specific site.

Origin

The word "systemic" comes from the Greek systēma, meaning a whole made of parts, and entered medical usage in the 19th century to describe processes affecting the entire body. The phrase "systemic therapy" became standard in oncology in the mid-20th century as chemotherapy emerged and doctors needed a way to distinguish whole-body drug treatment from localized approaches like surgery and radiation.

Significance in Asbestos Context

For most patients with pleural or peritoneal mesothelioma, systemic therapy is a central part of treatment because the disease often cannot be fully removed by surgery and tends to spread along tissue surfaces. The current first-line standard is typically a combination of immunotherapy (nivolumab plus ipilimumab) or platinum-based chemotherapy (cisplatin or carboplatin with pemetrexed), sometimes combined with bevacizumab. Patients should ask their oncologist which systemic regimen is recommended, whether they are eligible for clinical trials, and how response will be measured (usually by CT scan every 6-9 weeks). Records of every systemic therapy received (drug names, doses, dates, side effects, and response) are important both for ongoing medical decisions and as documentation of the cost and burden of the disease in a legal claim.

Example Sentence

After her mesothelioma was found to be unresectable, the oncologist recommended starting systemic therapy with a combination of immunotherapy drugs.

Related Terms

Chemotherapy, Immunotherapy, Pemetrexed, Cisplatin, Targeted Therapy, Clinical Trial

Notes

• Ask your oncologist to explain in writing which systemic regimen you are receiving, the expected duration, and how response will be assessed.
• Keep a personal log of infusion dates, drug names, and side effects. This record helps both your medical team and any legal claim documenting damages.
• Ask whether biomarker or molecular testing (such as BAP1, NF2, or PD-L1) could open the door to targeted therapy or a clinical trial.
• If you are offered chemotherapy, ask specifically whether immunotherapy or a combination approach has been considered, since first-line standards have shifted in recent years.
• Save all pharmacy receipts, insurance Explanation of Benefits statements, and out-of-pocket costs related to systemic therapy for your records.